Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Synergistic effects of a new beta-adrenergic blocker (pindolol) and isosorbidedinitrate during exercise in patients with coronary insufficiency

  • 23 Accesses

  • 12 Citations

Summary

23 male patients with coronary insufficiency on exertion underwent standardized work tests using a bicycle ergometer. In a double blind randomized trial they received oral doses of 2 mg pindolol (LB 46), 5 mg Isosorbidedinitrate (ISO), 2 mg pindolol + 5 mg isosorbidedinitrate (LBI 25) and a placebo. LBI 25, LB 46 and ISO all produced significant increases in the work performed before symptoms and signs appeared of coronary insufficiency. The mean increase in total work was: LBI 25 69%; LB 46 49%; and ISO 33%. The corresponding figures for work performed up to the time of appearance of ST-depression were: LBI 25 115%; LB 46 87%; and ISO 54%. A moderate synergism between ISO and LB 46 was found in 17 of the 23 patients. Tiredness in the legs during work was more common in patients taking beta-blocking agents. Nine patients complained of slight headache, mostly after LBI 25 and ISO.

This is a preview of subscription content, log in to check access.

References

  1. Adolfsson, L., Areskog, N.-H.: Effects of propranolol in patients with coronary insufficiency (in Swedish). Läkartidningen64, Suppl. III, 83–88 (1967).

  2. Adolfsson, L., Areskog, N.-H., Rasmuson, T.: Effects of alprenolol and sorbidnitrate during exercise in patients with coronary insufficiency. Europ. J. clin. Pharmacol.3, 68–73 (1971).

  3. Aravanis, Ch., Michaelides, G.: Results of the use of a new beta-adrenergic blocker (LB 46) in angina pectoris. Acta cardiol. (Brux.)25, 501–509 (1970).

  4. Areskog, N.-H., Adolfsson, L.: Effects of a cardio-selective beta-adrenergic blocker (ICI 50172) at exercise in angina pectoris. Brit. med. J.1969 II, 601–603.

  5. Areskog, N.-H., Hallén, A.: ECG at rest and ECG response to exercise. In A. Hallén, Angina pectoris. Acta chir. scand., Suppl.323, 70–88 (1964).

  6. Aronow, W.S., Kaplan, M.A.: Evaluation of propranolol and isosorbide dinitrate in angina pectoris. Curr. Ther. Res.11, 80–86 (1969).

  7. Aronow, W.S., Kaplan, M.A.: Propranolol combined with isosorbide dinitrate versus placebo in angina pectoris. New Engl. J. Med., 280 nr.16, 847–850 (1969).

  8. Gillam, P.M.S., Prichard, B.N.C.: Use of propranolol in angina pectoris. Brit. med. J.1965 II, 337.

  9. Giudicelli, J.-F., Schmitt, H., Boissier, J.: Studies on dl-4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB 46), a new potent beta adrenergic blocking drug. J. Pharmacol. exp. Ther.168, 116–126 (1969).

  10. Hamer, J., Grandjean, T., Melendez, L., Sowton, G.E.: Effect of propranolol (Inderal) in angina pectoris. Brit. med. J.1964 II, 720–723.

  11. Kaltenbach, M., Becker, H.J., Graef, V., Hunscha, H.: Zur Therapie der Angina pectoris mit Beta-Rezeptorenblockern. Med. Klin.65, 494–500 (1970).

  12. Kaltenbach, M.: Untersuchung über die Wirkung einer Kombination von Beta-Rezeptorenblockern mit Nitroglyzerinkörpern in der Therapie der Angina Pectoris. In: Aktuelle Probleme der β-Rezeptorenblockade, Intern. Symp. Kronberg/Taunus, 19.–20. X. 1968, pp. 149–159. Hrsg.: F. Bender. Stuttgart, New York: F. K. Schattauer Verlag 1970.

  13. Lang, E., Haas, W., Heck, J.: Zur klinischen Pharmakologie der Beta-Sympathikolyse. Eine vergleichende Prüfung von LB 46 und Propranolol. Med. Klin.65, 2206–2211 (1970).

  14. Levy, J.V.: Cardiovascular effects of prinodolol (LB 46), a potent beta-adrenergic receptor antagonist. J. clin. Pharmacol., July–August, 249–260 (1971).

  15. Rose, G.A.: The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull. Wld. Hlth. Org.27, 645–658 (1962).

  16. Russek, H.I.: Propranolol and isosorbide dinitrate synergism in angina pectoris. Amer. J. Cardiol.21, 44–54 (1968).

  17. Russek, H.I.: New dimension in angina pectoris therapy. Geriatrics, March 81–95 (1969).

  18. Sainani, G.S., Mukherjee, A.K.: A double-blind drug trial of a new beta adrenergic blocking agent LB 46 in the treatment of angina pectoris. In: XIth International Congress of Internal Medicine, Oct. 25–30, pp. 24–25 (1970).

  19. Sjöstrand, T.: (ed.) Clinical Physiology. Pathophysiological basis and practical application, pp. 515–529. Stockholm: Svenska Bokförlaget 1967.

  20. Srivastava, S.C., Dewar, H.A., Newell, D.J.: Double-blind trial of propranolol (Inderal) in angina of effert. Brit. med. J.1964 II, 724.

  21. Srivastava, B.N., Deshmankar, B.S., Vyas, G.P., Khare, R.P., Rao, V.S., Gupta, R.K.: Pilot studies on LB 46, a new beta receptor blocking agent in normal volunteers. J. Assoc. Phycns India19, 68 (1971).

  22. Storstein-Spilker, L.: The influence of the beta-receptor blocking agent LB 46, isosorbidedinitrate and their combination on the exercise-ecg. Cardiovascular Research, Abstracts, VI World Congress of Cardiology, p. 298, 1970.

  23. Westling, H.: In “Angina Pectoris. Nordic Symposium in Göteborg, Sweden 1969”. (Ed. Varnauskas, E., Werkö, L.). 175–187 (1969).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Adolfsson, L., Areskog, N.-., Furberg, C. et al. Synergistic effects of a new beta-adrenergic blocker (pindolol) and isosorbidedinitrate during exercise in patients with coronary insufficiency. Eur J Clin Pharmacol 5, 37–43 (1972). https://doi.org/10.1007/BF00560894

Download citation

Key words

  • Beta adrenergic receptor blockade
  • nitrates
  • placebo
  • coronary artery disease
  • exercise test